Primary immunodeficiency as a cause of immune-mediated kidney diseases

被引:1
|
作者
Zhang, Changming [1 ]
Liang, Dandan [1 ]
Liu, Zhihong [1 ]
机构
[1] Nanjing Univ, Jinling Hosp, Affiliated Hosp, Natl Clin Res Ctr Kidney Dis,Med Sch, Nanjing, Peoples R China
基金
中国国家自然科学基金;
关键词
autoimmunity; complement mediated kidney diseases; diagnosis and treatment; lupus nephritis; primary immunodeficiency; SYSTEMIC-LUPUS-ERYTHEMATOSUS; DEFICIENCY CAUSES; INTERFERON; AUTOIMMUNITY; COMPLEMENT; EXPRESSION; MUTATIONS; BAFF; TLR7;
D O I
10.1093/ndt/gfae117
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Primary immunodeficiency (PID) is no longer defined by infections alone, and autoimmunity is an accompanying manifestation of PID. Recurrent infections may trigger autoimmunity through molecular mimicry, bystander activation or superantigens. The diagnosis of PID is still challenging, but genetic analysis reveals the underlying link between PID and autoimmunity. Mutations in relevant genes affecting central and peripheral immune tolerance, regulatory T-cell function, expansion of autoreactive lymphocytes, antigen clearance, hyperactivation of type I interferon and nuclear factor-kappa B pathways have all been implicated in triggering autoimmunity in PID. Autoimmunity in PID leads to chronic inflammation, tissue damage and organ failure, and increases the mortality of patients with PID. The kidneys are inextricably linked with the immune system, and kidney diseases can be mediated by both infection and autoimmunity/inflammation in PID patients. The manifestations of kidney involvement in PID patients are very heterogeneous and include lupus nephritis, C3 glomerulopathy, kidney thrombotic microangiopathy, vasculitis and interstitial nephritis. Patients with PID-caused kidney diseases have defined immune function defects and may benefit from pathway-based biologics, stem cell transplantation or gene therapy. Early diagnosis and appropriate treatment of PID are crucial for reducing the mortality rate and improving organ function and quality of life.
引用
收藏
页码:1772 / 1784
页数:13
相关论文
共 50 条
  • [21] Splenectomy in the management of primary immune-mediated hemolytic anemia and primary immune-mediated thrombocytopenia in dogs
    Bestwick, Jason P.
    Skelly, Barbara J.
    Swann, James W.
    Glanemann, Barbara
    Bexfield, Nick
    Gkoka, Zeta
    Walker, David J.
    Silvestrini, Paolo
    Adamantos, Sophie
    Seth, Mayank
    Warland, James
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2022, 36 (04) : 1267 - 1280
  • [22] Immune-Mediated Muscle Diseases of the Horse
    Durward-Akhurst, S. A.
    Valberg, S. J.
    VETERINARY PATHOLOGY, 2018, 55 (01) : 68 - 75
  • [23] Immune-mediated Diseases of Nervous System
    Weissert, Robert
    Schulte-Mattler, Wilhelm J.
    KLINISCHE NEUROPHYSIOLOGIE, 2014, 45 (04) : 185 - 185
  • [24] Molecular mimicry and immune-mediated diseases
    Oldstone, MBA
    FASEB JOURNAL, 1998, 12 (13): : 1255 - 1265
  • [25] Genetics of immune-mediated inflammatory diseases
    David, T.
    Ling, S. F.
    Barton, A.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 193 (01): : 3 - 12
  • [26] Approach to Immune-mediated Ocular Diseases
    Knickelbein, Kelly E.
    Lassaline, Mary E.
    VETERINARY CLINICS OF NORTH AMERICA-EQUINE PRACTICE, 2024, 40 (02) : 275 - 286
  • [27] Adiponectin in inflammatory and immune-mediated diseases
    Fantuzzi, Giamila
    CYTOKINE, 2013, 64 (01) : 1 - 10
  • [28] Immune-Mediated CNS Diseases: a Review
    DeSena A.D.
    Current Physical Medicine and Rehabilitation Reports, 2017, 5 (3) : 134 - 142
  • [29] Epigenetics in Immune-Mediated Pulmonary Diseases
    Liu, Yu
    Li, Hui
    Xiao, Tao
    Lu, Qianjin
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2013, 45 (03) : 314 - 330
  • [30] ADALIMUMAB IN THE TREATMENT OF IMMUNE-MEDIATED DISEASES
    Lapadula, G.
    Marchesoni, A.
    Armuzzi, A.
    Blandizzi, C.
    Caporali, R.
    Chimenti, S.
    Cimaz, R.
    Cimino, L.
    Gionchetti, P.
    Girolomoni, G.
    Lionetti, P.
    Marcellusi, A.
    Mennini, F. S.
    Salvarani, C.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2014, 27 : 33 - 48